PF-07220060 + PF-07104091 + fulvestrant

This combination consists of PF-07220060 (Atirmociclib), a selective oral CDK4 inhibitor, PF-07104091, a selective oral CDK2 inhibitor, and fulvestrant, a selective estrogen receptor degrader (SERD). The regimen is under clinical investigation primarily for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, particularly in patients who have developed resistance to CDK4/6 inhibitors and endocrine therapy. PF-07220060 is designed to inhibit CDK4 selectively, aiming to reduce dose-limiting neutropenia associated with CDK6 inhibition, while PF-07104091 selectively inhibits CDK2, potentially addressing resistance mechanisms that arise after CDK4/6 inhibitor therapy. Fulvestrant acts by degrading the estrogen receptor, disrupting estrogen signaling in breast cancer cells. This combination targets cell cycle progression (via CDK4 and CDK2 inhibition) and hormonal signaling (via ER degradation) to provide a comprehensive blockade of proliferative pathways in breast cancer cells[5][7][3][1].

Other names

Atirmociclib + PF-07104091 + fulvestrant